Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


RNAi Start-Ups Continue Seeking, Attracting Support: Private Investors Like Nucleonics' Focus

This article was originally published in Start Up

Executive Summary

Nucleonics, like other companies competing in the new field of RNAi, started out with big ambitions. Even before its Series A financing ran out, the company decided to focus on clinical goals. Nucleonics has just received a $41 million financing meant to see two drug candidates, presently still in preclinical testing, get through Phase II. Investors like its focus. Meanwhile, Alnylam still has big plans, which it's now hoping to finance through the public markets.

You may also be interested in...

Nucleonics Inc.

Nucleonics Inc. has turned to plasmid DNA delivery technology as an answer to the siRNA delivery challenge. The company believes this approach could be an effective mechanism for selectively targeting viruses, and offers significant advantages over other methods for generating a gene silencing response in targeted cells

RNAi-Based Drug Development

Two issues dominate discussions over the business prospects for RNA interference-based therapeutics: the first is a basic pharmacological challenge: can a double-stranded RNAi be delivered inside a cell, and can it survive entry through the cell membrane with the physical integrity necessary to bind its target RNA and shut down protein production before it starts? The second is determining who has freedom to operate, in an area where patents enabling human therapeutic uses for RNAi are relatively fresh, and clinical data does not exist.

Alnylam Pharmaceuticals Inc.

Alnylam is a leader in the emerging field of RNA interference-based therapeutics development, and the first to land a deal with a Big Pharma (Merck). Its focus is to discover and develop therapies for a range of diseases including viral infection, oncology, and autoimmune diseases.

Related Content


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts